Skip to Content
Merck
All Photos(1)

Documents

1134233

USP

Citalopram hydrobromide

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile hydrobromide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C20H21FN2O · HBr
CAS Number:
Molecular Weight:
405.30
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

citalopram

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Br[H].CN(C)CCCC1(OCc2cc(ccc12)C#N)c3ccc(F)cc3

InChI

1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H

InChI key

WIHMBLDNRMIGDW-UHFFFAOYSA-N

Gene Information

human ... SLC6A4(6532)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Citalopram hydrobromide USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Potent and selective serotonin uptake inhibitor (Ki = 5.4 nM); antidepressant

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Pictograms

Health hazardExclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - STOT SE 3

Target Organs

Central nervous system

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 9

1 of 9

Escitalopram oxalate United States Pharmacopeia (USP) Reference Standard

USP

1249406

Escitalopram oxalate

USP

USP

1134244

Citalopram Related Compound A

Risperidone United States Pharmacopeia (USP) Reference Standard

USP

1604654

Risperidone

USP

USP

1224981

Donepezil hydrochloride

Escitalopram Oxalate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1733

Escitalopram Oxalate

Amlodipine besylate United States Pharmacopeia (USP) Reference Standard

USP

1029501

Amlodipine besylate

Escitalopram oxalate ≥98% (HPLC), powder

Sigma-Aldrich

E4786

Escitalopram oxalate

Valproic acid United States Pharmacopeia (USP) Reference Standard

USP

1708707

Valproic acid

Atorvastatin Calcium United States Pharmacopeia (USP) Reference Standard

USP

1044516

Atorvastatin Calcium

Yevheniia Mikheenko et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 40(6), 1395-1404 (2015-01-15)
Trait anxiety is a risk factor for the development and maintenance of affective disorders, and insights into the underlying brain mechanisms are vital for improving treatment and prevention strategies. Translational studies in non-human primates, where targeted neurochemical and genetic manipulations
Gordon F Buchanan et al.
The Journal of physiology, 592(19), 4395-4410 (2014-08-12)
Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in patients with refractory epilepsy. Defects in central control of breathing are important contributors to the pathophysiology of SUDEP, and serotonin (5-HT) system dysfunction may be involved. Here
M D Opal et al.
Molecular psychiatry, 19(10), 1106-1114 (2013-10-30)
Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert antidepressant actions with a faster-onset (5 days) than that of current antidepressants (14 days) in mice. Subchronic (5 days)
Mark R Davies et al.
Cell reports. Medicine, 1(5), 100076-100076 (2020-11-19)
There is an increasing expectation that computational approaches may supplement existing human decision-making. Frontloading of models for cardiac safety prediction is no exception to this trend, and ongoing regulatory initiatives propose use of high-throughput in vitro data combined with computational models
Jesper T Andreasen et al.
Brain research, 1601, 117-126 (2015-01-13)
Depression and anxiety often co-occur, and conventional monoamine-facilitating antidepressants show efficacy against symptoms in both disorders. Rodent studies indicate that antidepressant effects of monoamine-based antidepressants involve increased α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid glutamate receptor (AMPAR) neurotransmission, and positive allosteric modulators (PAMs) at

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service